ABO-CoV.617.2
/ Suzhou Abogen Biosci
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
August 23, 2022
A Study to Evaluate Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19) mRNA Vaccines
(clinicaltrials.gov)
- P1 | N=60 | Active, not recruiting | Sponsor: Suzhou Abogen Biosciences Co., Ltd. | Recruiting ➔ Active, not recruiting
Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
July 23, 2022
A Study to Evaluate Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19) mRNA Vaccines
(clinicaltrials.gov)
- P1 | N=60 | Recruiting | Sponsor: Suzhou Abogen Biosciences Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
June 28, 2022
A Study to Evaluate Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19) mRNA Vaccines
(clinicaltrials.gov)
- P1 | N=60 | Not yet recruiting | Sponsor: Suzhou Abogen Biosciences Co., Ltd.
New P1 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
1 to 3
Of
3
Go to page
1